Unveiling Viatris (VTRS) Q1 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Viatris Q1 Earnings Release: What's in Store for the Stock?
VTRS' Q1 results are likely to gain from new product launches in all major geographies.
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
Viatris to pay up to $335 million to resolve opioid-related claims
Viatris said on Monday it would pay up to a maximum of $335 million over nine years as part of a nationwide settlement to resolve opioid-related claims against the drugmaker.
Viatris Inc. (VTRS) Barclays 27th Annual Global Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) Barclays 27th Annual Global Healthcare Conference Call March 11, 2025 2:00 PM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good afternoon, everyone. Thank you all for joining us at the Barclays Healthcare Conference, continuing our spec pharma session for the day.
Viatris: A Unique S&P 500 'Fallen Angel' With Intriguing Potential
Viatris emerged from Pfizer's merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. Despite the recent stock plunge, VTRS trades at under 5x trailing earnings, making it an intriguing "dog collar" investment opportunity. The stock boasts strong profitability (A+) and valuation (A), but recent earnings miss raises concerns about future performance.
Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stock Of The Day: Why The Viatris Meltdown Ended Where It Did
Shares of Viatris Inc. NASDAQ are consolidating Friday. This follows yesterday's 15% selloff.
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert.
Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook
On Thursday, Viatris Inc. VTRS reported fourth-quarter 2024 sales of $3.52 billion, down 8% year over year, missing the consensus of $3.61 billion.
Viatris Inc. (VTRS) Q4 2024 Earnings Call Transcript
Viatris Inc. (NASDAQ:VTRS ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Ashwani Verma - UBS Chris Schott - JPMorgan Jason Gerberry - Bank of America Umer Raffat - Evercore Balaji Prasad - Barclays Operator Good morning everyone and welcome to the Viatris Q4 and Full Year 2024 Earnings Call. All participants will be in the listen-only mode.
